Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients
Authors:
- 16 January 2026
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 40 (1) , e70443
Abstract
The gold standard approach to the diagnosis of rejection in kidney transplant recipients currently relies on tissue obtained during biopsies. However, repeat performance of biopsies is cumbersome, and use of dd‐cfDNA in conjunction with eGFR may help inform whether ongoing rejection may be persistent after a diagnosis of rejection is made by biopsy and anti‐rejection treatment administered. In this single‐center prospective study, 52 patients with rejection were followed longitudinally over time with quarterly dd‐cfDNA measurements, of whom 78% had repeat biopsies to confirm the presence or absence of persistent rejection. With every 1 percentage point higher baseline (“first”) dd‐cfDNA levels drawn at time of enrollment, the odds of persistent rejection were 1.35 (95% CI 1.18‐1.55) higher. With every 1 percentage point increase in the slope of dd‐cfDNA levels over time, the odds of persistent rejection were 1.62 times higher (95% CI 1.10‐2.38). Models including only baseline and the slope of dd‐cfDNA provided moderate risk discrimination for rejection (c = 0.73), which improved to c = 0.75 with the addition of eGFR at baseline and change in eGFR over time. Monitoring of dd‐cfDNA may offer reasonable discrimination of the likelihood of persistent rejection following anti‐rejection therapy. Further validation of these findings is needed.Keywords
Funding Information
- Natera
This publication has 16 references indexed in Scilit:
- Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter studyAmerican Journal of Transplantation, 2025
- Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft RejectionKidney International Reports, 2025
- Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant RecipientsClinical Transplantation, 2024
- Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney TransplantTransplantation, 2024
- Follow‐up biopsies identify high rates of persistent rejection in pediatric kidney transplant recipients after treatment of T cell‐mediated rejectionPediatric Transplantation, 2023
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Use of a donor‐derived cell‐free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejectionPediatric Transplantation, 2022
- Incidence, risk factors, treatment, and consequences of antibody‐mediated kidney transplant rejection: A systematic reviewClinical Transplantation, 2021
- Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkersAmerican Journal of Transplantation, 2020
- Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS surveyClinical Transplantation, 2017